NYSE:TEVAPharmaceuticals
Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress
Teva Pharmaceutical Industries reported its 2025 results on January 28, 2026, with revenue rising to US$17.26 billion and net income improving to US$1.41 billion, alongside continued momentum in branded drugs like AUSTEDO, UZEDY, and AJOVY.
The earnings release underscored Teva’s ongoing shift from a primarily generics-focused business toward higher-margin innovative medicines, supported by cost savings initiatives and late-stage pipeline progress.
We’ll now examine how Teva’s improving...